BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at
the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin
(trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue
to offer new and better treatment options for breast cancer patients allowing
women to live longer or remain disease-free for longer if the medicines are
given before and after surgery as well as in advanced stages of disease.

Key data being presented include:
- Herceptin before surgery: Results from the NOAH (NeOAdjuvant Herceptin)
phase III study showed that women with locally advanced HER2-positive
breast cancer who started a combination of Herceptin and standard
chemotherapy prior to surgery had a significantly greater chance of
living free of their disease (event-free survival) three years after
initiation of treatment as compared to women who were receiving pre-
operative chemotherapy alone.
- Xeloda in early breast cancer: Early data from an independent study in
Finland and Sweden indicate that the chemotherapy pill Xeloda, which is
already proven in advanced breast cancer, may also reduce the
recurrence of early breast cancer and help women live longer. This is
one of 20 Xeloda abstracts that have been accepted for presentation
during SABCS.
- Avastin in advanced breast cancer: First efficacy results from the
largest ever safety study of Avastin in a real-life setting, which
involved more than 2,000 patients with locally recurrent or metastatic
breast cancer, confirm that Avastin can be used with a broad range of
chemotherapy treatments giving patients a median of almost 10 months
without their disease getting worse. The results, which are one of 24
separate Avastin data presentations during SABCS, confirm that Avastin
based therapy is essential for improving the lives of women with
advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each
success helps lay the foundation for the next step forward," said William M.
Burns, CEO Division Roche Pharmaceuticals. "These results show that we are
making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating
disease at all stages," he added.

The above mentioned studies and data represent the latest results of
clinical research for each treatment and are not necessarily part of the
indicated licence in each country. For detailed label information, visit the
website of your health authority or the EMEA website
http://www.emea.europa.eu/

Note to Editors

Breast cancer is the most common cancer among women worldwide.(i) Each
year more than one million new cases of breast cancer are diagnosed worldwide,
and nearly 400,000 people will die of the disease annually. (ii) In HER2-
positive breast cancer, increased quantities of the HER2 protein are present
on the surface of the tumour cells. This is known as 'HER2-positivity'. High
levels of HER2 are present in a particularly aggressive form of the disease
which responds poorly to chemotherapy. Research shows that HER2-positivity
affects approximately 20-30 percent of women with breast cancer.(iii)

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, and is a market
leader in virology. It is also active in other major therapeutic areas such as
autoimmune diseases, inflammatory and metabolic disorders and diseases of the

central nervous system. In 2007 sales by the Pharmaceuticals Division totaled
36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3
billion francs. Roche has R&D agreements and strategic alliances with numerous
partners, including majority ownership interests in Genentech and Chugai, and
invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group
employs about 80,000 people. Additional information is available on the
Internet at http://www.roche.com

(Date:9/27/2017)... , Sept. 27, 2017 Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...

(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...

(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...

(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...

(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...